Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial related observations

Molecular Urology

Volumn 4, Issue 3, 2000, Pages

  Bruchovsky, N ^a   Klotz, L H ^a   Sadar, M ^a   Crook, J M ^a   Hoffart, D ^a   Godwin, L ^a   Warkentin, M ^a   Gleave, M E ^a   Goldenberg, S L ^a   Stone, N ^a   D'Amico, A ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE; FINASTERIDE; FLUTAMIDE; FORSKOLIN; GONADORELIN AGONIST; LEUPRORELIN; MESSENGER RNA; METRIBOLONE; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; TUMOR GROWTH;

ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DISEASE PROGRESSION; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TESTOSTERONE; TIME FACTORS;

EID: 0033756014     PISSN: 10915362     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Effects of intermittent androgen suppression on androgen-dependent tumors: Apoptosis and serum prostate specific antigen
2. Intermittent endocrine therapy for prostate cancer
3. Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report
4. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study
5. Intermittent endocrine therapy of prostate cancer
6. Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer
7. Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy
8. Intermittent androgen deprivation for clinically localized prostate cancer: Initial experience
9. A pilot study of intermittent androgen deprivation in advanced prostate cancer
10. Intermittent androgen suppression for the treatment of prostate cancer
11. A Phase II study of intermittent androgen suppression (IAS) in men with a rising serum PSA after radiation for localized prostate cancer
12. Intermittent androgen suppression (IAS) in advanced or inoperable prostate cancer
13. Intermittent androgen suppression in the management of prostate cancer
14. Intermittent androgen deprivation in prostate cancer patients: Factors predictive of prolonged time off therapy
15. Prostate cancer: Molecular biology of early progression to androgen independence
16. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model
17. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways
18. Activation of the human AR through a protein kinase A signaling pathway
19. Androgens and antiandrogens
20. Androgenic regulation of a tissue specific isoenzyme of acid phosphatase in rat ventral prostate
21. The effects of orchidectomy on skeletal metabolism in metastatic prostate cancer
22. 6-GnRH)
23. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma
24. Osteoporosis after orchiectomy for prostate cancer
25. Effect of finasteride, a 5α-reductase inhibitor on prostate tissue androgens and prostate-specific antigen
26. Finasteride, an inhibitor of 5α-reductase, suppresses prostate dihydrotestosterone in men with benign prostatic hyperplasia
27. Finasteride
28. Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5α-reductase inhibitor finasteride
29. Characterization of 5α-reductase gene expression in stroma and epithelium of human prostate
30. Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the Shionogi carcinoma
31. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen independence after castration in the Shionogi tumor model
32. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer
33. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma
34. Effect of tumor progression on the androgenic regulation of the androgen receptor, TRPM-2 and YPT1 genes in the Shionogi carcinoma
35. Intermittent therapy for prostate cancer
36. Hormonal control of growth and progression in tumors of Nb rats and a theory of action